Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis

Sandra R. Reynolds, Esteban Celis, Alessandro Sette, Ruth Oratz, Richard L. Shapiro, Dean Johnston, Marilena Fotino, Jean Claude Bystryn

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

With the discovery of increasing numbers of tumor antigens, there is a need to rapidly determine whether these antigens and the individual peptides they express are able to stimulate immune responses in vivo and thus, can be used to construct cancer vaccines. In this study we used the method of vaccine-induced immune response (VIIR) analysis to identify multiple immunogenic peptide epitopes derived from several melanoma associated antigens and presented by HLA-A*03, A*11 and B*07. Thirty-one patients with melanoma were immunized to a polyvalent vaccine containing multiple antigens, including MAGE-3, Melan A/MART-1, gp100 and tyrosinase. Their peripheral blood was tested for peptide-specific, vaccine-induced CD8+ T cell responses before and after immunization using an enzyme-linked immune spot (ELISPOT) assay with panels of peptides restricted by these three alleles. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLA-A*03, A*11 or B*07. Overall, 60% of the 20 peptides studied were recognized by at least one patient and 50% of the patients showed a vaccine-induced CD8+ T cell response to at least one peptide that matched their HLA specificity. We conclude that VIIR analysis is an effective strategy to directly identify immunogenic peptides that are good candidates for vaccine construction. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalJournal of Immunological Methods
Volume244
Issue number1-2
DOIs
StatePublished - Oct 20 2000

Fingerprint

HLA-A Antigens
Melanoma
Vaccines
Peptides
MART-1 Antigen
Melanoma-Specific Antigens
T-Lymphocytes
Antigens
Cancer Vaccines
Subunit Vaccines
Monophenol Monooxygenase
Neoplasm Antigens
Epitopes
Immunization
Alleles
Enzymes

Keywords

  • CD8+ T cells
  • ELISPOT
  • Melanoma vaccine
  • Peptide
  • T cell epitope

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. / Reynolds, Sandra R.; Celis, Esteban; Sette, Alessandro; Oratz, Ruth; Shapiro, Richard L.; Johnston, Dean; Fotino, Marilena; Bystryn, Jean Claude.

In: Journal of Immunological Methods, Vol. 244, No. 1-2, 20.10.2000, p. 59-67.

Research output: Contribution to journalArticle

Reynolds, Sandra R. ; Celis, Esteban ; Sette, Alessandro ; Oratz, Ruth ; Shapiro, Richard L. ; Johnston, Dean ; Fotino, Marilena ; Bystryn, Jean Claude. / Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. In: Journal of Immunological Methods. 2000 ; Vol. 244, No. 1-2. pp. 59-67.
@article{7a8d55a31d5c48d9ac884516b6b551c2,
title = "Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis",
abstract = "With the discovery of increasing numbers of tumor antigens, there is a need to rapidly determine whether these antigens and the individual peptides they express are able to stimulate immune responses in vivo and thus, can be used to construct cancer vaccines. In this study we used the method of vaccine-induced immune response (VIIR) analysis to identify multiple immunogenic peptide epitopes derived from several melanoma associated antigens and presented by HLA-A*03, A*11 and B*07. Thirty-one patients with melanoma were immunized to a polyvalent vaccine containing multiple antigens, including MAGE-3, Melan A/MART-1, gp100 and tyrosinase. Their peripheral blood was tested for peptide-specific, vaccine-induced CD8+ T cell responses before and after immunization using an enzyme-linked immune spot (ELISPOT) assay with panels of peptides restricted by these three alleles. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLA-A*03, A*11 or B*07. Overall, 60{\%} of the 20 peptides studied were recognized by at least one patient and 50{\%} of the patients showed a vaccine-induced CD8+ T cell response to at least one peptide that matched their HLA specificity. We conclude that VIIR analysis is an effective strategy to directly identify immunogenic peptides that are good candidates for vaccine construction. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "CD8+ T cells, ELISPOT, Melanoma vaccine, Peptide, T cell epitope",
author = "Reynolds, {Sandra R.} and Esteban Celis and Alessandro Sette and Ruth Oratz and Shapiro, {Richard L.} and Dean Johnston and Marilena Fotino and Bystryn, {Jean Claude}",
year = "2000",
month = "10",
day = "20",
doi = "10.1016/S0022-1759(00)00254-4",
language = "English (US)",
volume = "244",
pages = "59--67",
journal = "Journal of Immunological Methods",
issn = "0022-1759",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis

AU - Reynolds, Sandra R.

AU - Celis, Esteban

AU - Sette, Alessandro

AU - Oratz, Ruth

AU - Shapiro, Richard L.

AU - Johnston, Dean

AU - Fotino, Marilena

AU - Bystryn, Jean Claude

PY - 2000/10/20

Y1 - 2000/10/20

N2 - With the discovery of increasing numbers of tumor antigens, there is a need to rapidly determine whether these antigens and the individual peptides they express are able to stimulate immune responses in vivo and thus, can be used to construct cancer vaccines. In this study we used the method of vaccine-induced immune response (VIIR) analysis to identify multiple immunogenic peptide epitopes derived from several melanoma associated antigens and presented by HLA-A*03, A*11 and B*07. Thirty-one patients with melanoma were immunized to a polyvalent vaccine containing multiple antigens, including MAGE-3, Melan A/MART-1, gp100 and tyrosinase. Their peripheral blood was tested for peptide-specific, vaccine-induced CD8+ T cell responses before and after immunization using an enzyme-linked immune spot (ELISPOT) assay with panels of peptides restricted by these three alleles. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLA-A*03, A*11 or B*07. Overall, 60% of the 20 peptides studied were recognized by at least one patient and 50% of the patients showed a vaccine-induced CD8+ T cell response to at least one peptide that matched their HLA specificity. We conclude that VIIR analysis is an effective strategy to directly identify immunogenic peptides that are good candidates for vaccine construction. Copyright (C) 2000 Elsevier Science B.V.

AB - With the discovery of increasing numbers of tumor antigens, there is a need to rapidly determine whether these antigens and the individual peptides they express are able to stimulate immune responses in vivo and thus, can be used to construct cancer vaccines. In this study we used the method of vaccine-induced immune response (VIIR) analysis to identify multiple immunogenic peptide epitopes derived from several melanoma associated antigens and presented by HLA-A*03, A*11 and B*07. Thirty-one patients with melanoma were immunized to a polyvalent vaccine containing multiple antigens, including MAGE-3, Melan A/MART-1, gp100 and tyrosinase. Their peripheral blood was tested for peptide-specific, vaccine-induced CD8+ T cell responses before and after immunization using an enzyme-linked immune spot (ELISPOT) assay with panels of peptides restricted by these three alleles. The peptides were selected for immunogenic potential based on their strong binding affinity in vitro to HLA-A*03, A*11 or B*07. Overall, 60% of the 20 peptides studied were recognized by at least one patient and 50% of the patients showed a vaccine-induced CD8+ T cell response to at least one peptide that matched their HLA specificity. We conclude that VIIR analysis is an effective strategy to directly identify immunogenic peptides that are good candidates for vaccine construction. Copyright (C) 2000 Elsevier Science B.V.

KW - CD8+ T cells

KW - ELISPOT

KW - Melanoma vaccine

KW - Peptide

KW - T cell epitope

UR - http://www.scopus.com/inward/record.url?scp=0034692682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034692682&partnerID=8YFLogxK

U2 - 10.1016/S0022-1759(00)00254-4

DO - 10.1016/S0022-1759(00)00254-4

M3 - Article

C2 - 11033019

AN - SCOPUS:0034692682

VL - 244

SP - 59

EP - 67

JO - Journal of Immunological Methods

JF - Journal of Immunological Methods

SN - 0022-1759

IS - 1-2

ER -